Virus-specific T cells for therapy - Approaches, problems, solutions

European Journal of Cell Biology

Volumn 91, Issue 1, 2012, Pages 97-101

  Moosmann, Andreas ^a   Hammerschmidt, Wolfgang ^b   Kolb, Hans Jochem ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adoptive T cell therapy; Cytomegalovirus; Epstein Barr virus; T cell transfer

Indexed keywords

FOSCARNET; GANCICLOVIR; VIRUS ANTIGEN; VIRUS VECTOR;

ADOPTIVE T CELL THERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELL THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR; EPSTEIN BARR VIRUS; GENE TRANSFER; GENETIC TRANSFECTION; GRAFT RECIPIENT; HUMAN; HUMAN CELL CULTURE; IMMUNOGENICITY; INFECTION RISK; LYMPHOPROLIFERATIVE DISEASE; NEUTROPENIA; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SHORT SURVEY; VIRUS CELL TRANSFORMATION; VIRUS INFECTION; VIRUS REACTIVATION;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, VIRAL; DENDRITIC CELLS; GENE EXPRESSION REGULATION, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VIRUS ACTIVATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4;

EID: 84855919551     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2011.04.001     Document Type: Short Survey

References (48)

1. Adhikary D., Behrends U., Boerschmann H., Pfunder A., Burdach S., Moosmann A., Witter K., Bornkamm G.W., Mautner J. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS One 2007, 2:e583.
2. Adhikary D., Behrends U., Moosmann A., Witter K., Bornkamm G.W., Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp. Med. 2006, 203:995-1006.
3. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96.
4. Bendle G.M., Linnemann C., Hooijkaas A.I., Bies L., de Witte M.A., Jorritsma A., Kaiser A.D., Pouw N., Debets R., Kieback E., Uckert W., Song J.Y., Haanen J.B., Schumacher T.N. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 2010, 16:565-570.
5. Brestrich G., Zwinger S., Fischer A., Schmuck M., Rohmhild A., Hammer M.H., Kurtz A., Uharek L., Knosalla C., Lehmkuhl H., Volk H.D., Reinke P. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am. J. Transplant. 2009, 9:1679-1684.
6. Brosterhus H., Brings S., Leyendeckers H., Manz R.A., Miltenyi S., Radbruch A., Assenmacher M., Schmitz J. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur. J. Immunol. 1999, 29:4053-4059.
7. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., Proesch S., Reinke P., Volk H.D., Lehmkuhl H., Kern F. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8T cells. J. Exp. Med. 2005, 201:1031-1036.
8. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., Assenmacher M., Billingham L., Steward C., Crawley C., Olavarria E., Goldman J., Chakraverty R., Mahendra P., Craddock C., Moss P.A. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 2005, 202:379-386.
9. Comoli P., Labirio M., Basso S., Baldanti F., Grossi P., Furione M., Vigano M., Fiocchi R., Rossi G., Ginevri F., Gridelli B., Moretta A., Montagna D., Locatelli F., Gerna G., Maccario R. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002, 99:2592-2598.
10. Cox K.L., Lawrence-Miyasaki L.S., Garcia-Kennedy R., Lennette E.T., Martinez O.M., Krams S.M., Berquist W.E., So S.K., Esquivel C.O. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995, 59:524-529.
11. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Loffler J., Grigoleit U., Moris A., Rammensee H.G., Kanz L., Kleihauer A., Frank F., Jahn G., Hebart H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
12. Falk C.S., Mach M., Schendel D.J., Weiss E.H., Hilgert I., Hahn G. NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J. Immunol. 2002, 169:3257-3266.
13. Feuchtinger T., Matthes-Martin S., Richard C., Lion T., Fuhrer M., Hamprecht K., Handgretinger R., Peters C., Schuster F.R., Beck R., Schumm M., Lotfi R., Jahn G., Lang P. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol. 2006, 134:64-76.
14. Feuchtinger T., Opherk K., Bethge W.A., Topp M.S., Schuster F.R., Weissinger E.M., Mohty M., Or R., Maschan M., Schumm M., Hamprecht K., Handgretinger R., Lang P., Einsele H. Adoptive transfer of pp-65 specific T-cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
15. Gottschalk S., Ng C.Y., Perez M., Smith C.A., Sample C., Brenner M.K., Heslop H.E., Rooney C.M. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001, 97:835-843.
16. Hanley P.J., Cruz C.R., Savoldo B., Leen A.M., Stanojevic M., Khalil M., Decker W., Molldrem J.J., Liu H., Gee A.P., Rooney C.M., Heslop H.E., Dotti G., Brenner M.K., Shpall E.J., Bollard C.M. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
17. Haque T., Wilkie G.M., Jones M.M., Higgins C.D., Urquhart G., Wingate P., Burns D., McAulay K., Turner M., Bellamy C., Amlot P.L., Kelly D., MacGilchrist A., Gandhi M.K., Swerdlow A.J., Crawford D.H. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
18. Heslop H.E., Slobod K.S., Pule M.A., Hale G.A., Rousseau A., Smith C.A., Bollard C.M., Liu H., Wu M.F., Rochester R.J., Amrolia P.J., Hurwitz J.L., Brenner M.K., Rooney C.M. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
19. Hettich E., Janz A., Zeidler R., Pich D., Hellebrand E., Weissflog B., Moosmann A., Hammerschmidt W. Genetic design of an optimized packaging cell line for gene vectors transducing human B cells. Gene Ther. 2006, 13:844-856.
20. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 2007, 25:587-617.
21. Hong G.K., Gulley M.L., Feng W.H., Delecluse H.J., Holley-Guthrie E., Kenney S.C. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 2005, 79:13993-14003.
22. Khanna R., Bell S., Sherritt M., Galbraith A., Burrows S.R., Rafter L., Clarke B., Slaughter R., Falk M.C., Douglass J., Williams T., Elliott S.L., Moss D.J. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10391-10396.
23. Klenovsek K., Weisel F., Schneider A., Appelt U., Jonjic S., Messerle M., Bradel-Tretheway B., Winkler T.H., Mach M. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 2007, 110:3472-3479.
24. Knabel M., Franz T.J., Schiemann M., Wulf A., Villmow B., Schmidt B., Bernhard H., Wagner H., Busch D.H. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 2002, 8:631-637.
25. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
26. Kruschinski A., Moosmann A., Poschke I., Norell H., Chmielewski M., Seliger B., Kiessling R., Blankenstein T., Abken H., Charo J. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17481-17486.
27. Liang X., Weigand L.U., Schuster I.G., Eppinger E., van der Griendt J.C., Schub A., Leisegang M., Sommermeyer D., Anderl F., Han Y., Ellwart J., Moosmann A., Busch D.H., Uckert W., Peschel C., Krackhardt A.M. A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire. J. Immunol. 2010, 184:1617-1629.
28. Limaye A.P. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 2002, 35:866-872.
29. Ljungman P. Risk assessment in haematopoietic stem cell transplantation: viral status. Best Pract. Res. Clin. Haematol. 2007, 20:209-217.
30. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003, 102:4255-4260.
31. Moosmann A., Bigalke I., Tischer J., Schirrmann L., Kasten J., Tippmer S., Leeping M., Prevalsek D., Jaeger G., Ledderose G., Mautner J., Hammerschmidt W., Schendel D.J., Kolb H.J. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960-2970.
32. Moosmann A., Khan N., Cobbold M., Zentz C., Delecluse H.J., Hollweck G., Hislop A.D., Blake N.W., Croom-Carter D., Wollenberg B., Moss P.A., Zeidler R., Rickinson A.B., Hammerschmidt W. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 2002, 100:1755-1764.
33. Moss P., Rickinson A. Cellular immunotherapy for viral infection after HSC transplantation. Nat. Rev. Immunol. 2005, 5:9-20.
34. Pappworth I.Y., Wang E.C., Rowe M. The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J. Virol. 2007, 81:474-482.
35. Peggs K.S., Verfuerth S., Pizzey A., Khan N., Guiver M., Moss P.A., Mackinnon S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362:1375-1377.
36. Reusser P., Riddell S.R., Meyers J.D., Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
37. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
38. Rooney C.M., Smith C.A., Ng C.Y., Loftin S., Li C., Krance R.A., Brenner M.K., Heslop H.E. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9-13.
39. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., Srivastava D.K., Bowman L.C., Krance R.A., Brenner M.K., Heslop H.E. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-1555.
40. Schub A., Schuster I.G., Hammerschmidt W., Moosmann A. CMV-specific TCR-transgenic T cells for immunotherapy. J. Immunol. 2009, 183:6819-6830.
41. Sokos D.R., Berger M., Lazarus H.M. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2002, 8:117-130.
42. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., Nelson J.A., Picker L.J. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202:673-685.
43. van Loenen M.M., de Boer R., Amir A.L., Hagedoorn R.S., Volbeda G.L., Willemze R., van Rood J.J., Falkenburg J.H., Heemskerk M.H. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10972-10977.
44. von Bergwelt-Baildon M.S., Vonderheide R.H., Maecker B., Hirano N., Anderson K.S., Butler M.O., Xia Z., Zeng W.Y., Wucherpfennig K.W., Nadler L.M., Schultze J.L. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002, 99:3319-3325.
45. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995, 333:1038-1044.
46. Wiesner M., Zentz C., Hammer M.H., Cobbold M., Kern F., Kolb H.J., Hammerschmidt W., Zeidler R., Moosmann A. Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines. Eur. J. Immunol. 2005, 35:2110-2121.
47. Wiesner M., Zentz C., Mayr C., Wimmer R., Hammerschmidt W., Zeidler R., Moosmann A. Conditional immortalization of human B cells by CD40 ligation. PLoS One 2008, 3:e1464.
48. Zentz C., Wiesner M., Man S., Frankenberger B., Wollenberg B., Hillemanns P., Zeidler R., Hammerschmidt W., Moosmann A. Activated B cells mediate efficient expansion of rare antigen-specific T cells. Hum. Immunol. 2007, 68:75-85.